Joecrack Concept

Latest Recruitment and Scholarships




  • Home
  • News
  • Job
  • Education
  • Post Utme/Direct Entry
  • Scholarships
  • Health
  • Entertainment
  • About Us
    • Contact Us
You are here: Home / Hydroxychloroquine has no impact on COVID-19, -World Health Organisation says

Hydroxychloroquine has no impact on COVID-19, -World Health Organisation says

June 18, 2020 by admin Leave a Comment

Spread the love

The World Health Organization (WHO) has stopped its Solidarity Trial arm that researches into the use of Hydroxychloroquine to effectively treat patients with COVID-19.

 

It said that several studies have indicated that Hydroxychloroquine (an anti-malaria drug) has no impact whatsoever on the virus, and does not result in the reduction of mortality of hospitalised COVID-19 patients.

 

This is coming days after U.S Food and Drug Administration (FDA) revoked the emergency authorization for Hydroxychloroquine to treat hospitalized COVID-19 patients, amidst several evidences that it could cause serious side-effects, and that it does not work.

The World Health Organisation made this known yesterday in a statement.

 

It said, “The Solidarity Trial’s Hydroxychloroquine arm is being stopped, on the basis of evidence showing it does not reduce mortality for hospitalised COVID-19 patients.”

On Tuesday, researchers at the University of Oxford in England reported that a commonly used steroid called dexamethasone can help COVID-19 patients on ventilators survive the illness, although the data from that trial have not be made public.

The WHO described the initial clinical trial results from dexamethasone as a welcome development, and can be lifesaving for treating patients who are critically ill with COVID-19.

It however said it will carry out an in-depth analysis of the intervention with the new drug, before issuing clinical guidance on how and when it should be used.

Recall that on the 25th of May 2020, the WHO suspended the use of Hydroxychloroquine in Solidarity Trial, multi-country trial, for the treatment of COVID-19, over safety concerns. It said a report published by Lancet, indicated that more people were dying from the use of the drug to combat COVID-19.

Later on the 4th of June 2020, it announced the resumption of clinical trials of the anti-malaria drug – Hydroxychloroquine, to determine its efficacy in the prevention and treatment COVID-19. The WHO based its decision to rescind on its prior stance on the fact that there was no cogent reason to halt the drug use for trial based on review of available data by its Safety Committee.

Share this:

  • Twitter
  • Facebook

Related

Filed Under: Uncategorized

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Join Us on FaceBook for direct Update

https://www.facebook.com/https://web.Joecrack-Concept-106861524228249/?view_public_for=106861524228249




Recent Posts

  • Why you will receive Low disbursement with NYIF – Joecrackconcept
  • Npower Agro Deployment List of Shortlisted Candidates for Batch C 2021 – See How to Check
  • NYSC COVID-19 Test Form – NYSC NCDC Covid-19 RDT Testing Verification Slip
  • NYSC Documents for Married Women: NYSC Registration Requirement for all Married Women
  • Federal University of Technology AKURE (FUTA) Recruitment Form Portal

Trendings

CBN Recruitment

Inec Recruitment

Nigeria Navy Recruitment

Federal Government  Loan and Grant

Civil Defence Recruitment

NDLEA Recruitment

Npower Recruitment

Waec Recruitment

PYES registration

 NNPC Recruitment

Nigeria Customs Recruitment

 Nigeria Airforce Recruitment

Nigeria Police Recruitment

 Nigerian Army Recruitment

 DSS Recruitment

NDDC Recruitment

 NAFDAC Recruitment

 Nigeria Immigration Service Recruitment

FRSC Recruitment

FCSC Recruitment

 Federal Fire Service Recruitment

 Federal Government Jobs in Nigeria

Copyright © 2021 · Joecrack Concept.